Please assess the completion status of the following clinical trial:

Trial Title: LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the trunk and/or limbs~* Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the Body Surface Area (BSA)~* An Investigator's Global Assessment of disease severity (IGA) of at least mild at Day 0 (Visit 1)~* A modified PASI (m-PASI) score of at least 2 at Day 0 (Visit 1)~* A target lesion of a minimum of 5 cm at its longest axis and preferably not located on the extensor surface on an elbow or knee, scoring at least 1 for each of redness, thickness and scaliness, and at least 4 in total by the Investigator's Assessment of Severity of the Target Lesion~Exclusion Criteria:~* Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:~  * etanercept - within 4 weeks prior to randomisation~ * adalimumab, infliximab - within 8 weeks prior to randomisation~ * ustekinumab - within 16 weeks prior to randomisation~ * other products - within 4 weeks/5 half-lives prior to randomisation (whichever is longer)~* Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants) within 4 weeks prior to randomisation.~* Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.~* PUVA therapy within 4 weeks prior to randomisation.~* UVB therapy within 2 weeks prior to randomisation.~* Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within 2 weeks prior to randomisation.~* Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D analogues or prescription shampoos within 2 weeks prior to randomisation.~* Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors) during the trial.~* Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.~* Previously randomised in this trial or any previously conducted trial of LEO 90100.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 90100 (Type: EXPERIMENTAL): LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
- Vehicle (Type: PLACEBO_COMPARATOR): Aerosol foam vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).